Despite treatment advancements with the introduction of HDMTX and rituximab, up to half of patients will have disease relapse, and 10%–15% may have primary refractory disease.

Bowel side effects do not differ between patients with localized prostate cancer who receive external beam radiation therapy using protons vs photons, investigators reported in a late-breaking ...

The researchers assessed TROP2 expression in 19 patient samples and found that 52% had high TROP2 expression (H-score ≥100; mean 123.6±90; range, 0-248). A post hoc analysis showed that OS positively ...

Intervention participants were more likely to complete screening and to have detection of advanced colorectal neoplasia.

Updated results from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib and dexamethasone “as a potential new standard of care,” according to Vania Hungria, MD, PhD.

Fedratinib can reduce symptoms and spleen volume in patients with myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs), according to research presented at the ASH ...

Enfortumab vedotin may be a treatment option for patients with advanced head and neck cancer that is not amenable to definitive local therapy, researchers say. They reported phase 2 results with ...

Breast cancer prevention efforts should include population-wide policies and regulations to reduce air pollution, according to researchers.

Researchers sought to determine whether CAR-T therapy would be safe and effective in patients with CLL and Richter transformation.

Lower cumulative incidence reported for two-year physician-scored toxicity and late-grade ≥2 toxicity with MRI guidance.

Researchers conducted a 10-year nationwide retrospective matched cohort study to compare the risk for cancer in people with multiple sclerosis and a matched sample.

Researchers sought to determine whether it would be beneficial to add inotuzumab to the CALGB 10403 pediatric regimen in the treatment of young adults with CD22-positive B-ALL.